CASI Pharmaceuticals (CASI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Which has more risk and volatility, CASI or GANX?

CASI Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Which has preferable earnings and valuation, CASI or GANX?

Gain Therapeutics has lower revenue, but higher earnings than CASI Pharmaceuticals. Gain Therapeutics is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$31.56M	0.79	-$39.26M	-$2.89	-0.70
Gain Therapeutics	$50K	1,488.33	-$20.41M	-$0.63	-3.29

Do analysts prefer CASI or GANX?

CASI Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 97.04%. Gain Therapeutics has a consensus price target of $7.86, suggesting a potential upside of 279.57%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Do institutionals and insiders hold more shares of CASI or GANX?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 7.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is CASI or GANX more profitable?

Gain Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -148.55%. Gain Therapeutics' return on equity of -289.10% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-148.55%	-972.55%	-99.07%
Gain Therapeutics	N/A	-289.10%	-155.11%

Does the media favor CASI or GANX?

In the previous week, Gain Therapeutics had 11 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 11 mentions for Gain Therapeutics and 0 mentions for CASI Pharmaceuticals. Gain Therapeutics' average media sentiment score of 0.87 beat CASI Pharmaceuticals' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Gain Therapeutics	Positive

Summary

Gain Therapeutics beats CASI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.